

AURORA 1/12 DNK





AURORA 1/12 DNK

Medical Cannabis
Product distributed in the UK

Active ingredient: <1% THC
Approx. 12% CBD
Dominant: Hybrid
Cultivar: Cannatonic



Ingredients:



Shown as a percentage of the total terpene content.
Percentages are averages over multiple batches.







Terpene ¹	β -myrcene	Guaiol
Scent	woody, fruity	fresh, pine-like

1. Russo E.B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163: 1344-1364.

TITRATION GUIDE

- There is currently no uniform starting dose for cannabis products nor uniform dosing information.
- Patients are recommended to slowly titrate up to find their optimal dose for maximum therapeutic effects and minimal adverse effects.
- Timing of onset depends on mode of administration.

Onset and duration of effects for inhalation and oral administration²

	Inhalation	Oral administration
Onset of Effect	 Within seconds to minutes	 Within 30 minutes to 2 hours
Peak Effects	 Full effects peak within 30 minutes	 Full effects peak within 4 hours
Duration of Effect	 Up to 6 hours or longer	 Up to 12 hours or longer

Adverse events should be reported. Reporting forms and information can be found at:
www.mhra.gov.uk/yellowcard

Adverse events should also be reported to:
[IPS Pharma | medicalcannabis@ipsspecials.com](mailto:medicalcannabis@ipsspecials.com) | 0800 644 0747



AURORA[®]

Aurora Medicine UK Limited | 5th Floor | 14-16 Dowgate Hill | London
EC4R 2SU | United Kingdom

2. Minister of Health HC, Health Canada. Health Effects of Cannabis.; 2017.